INKT — Mink Therapeutics Income Statement
0.000.00%
- $34.64m
- $33.04m
Annual income statement for Mink Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.69 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 23 | 14.6 | 28 | 30.9 | 22.9 |
Operating Profit | -22.3 | -14.6 | -28 | -30.9 | -22.9 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -23.8 | -16.2 | -30.2 | -28 | -22.5 |
Net Income After Taxes | -23.8 | -16.2 | -30.2 | -28 | -22.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -23.8 | -16.2 | -30.2 | -28 | -22.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -23.8 | -16.2 | -30.2 | -28 | -22.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.75 | -1.87 | -1.17 | -0.831 | -0.654 |